Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields



Publication Date Range:


Document Data


Document Type:






Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page


Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?

Filetype[PDF-696.91 KB]

  • English

  • Details:

    • Alternative Title:
      Clin Endocrinol (Oxf)
    • Description:

      Routine monitoring after the initial treatment of differentiated thyroid cancer (DTC) includes periodic cervical ultrasonography (US) and measurement of serum thyroglobulin (Tg) during thyrotrophin (TSH) suppression and after recombinant human TSH (rhTSH) stimulation. The aim of our study was to evaluate the utility of repeated rhTSH-stimulated Tg measurements in patients with DTC who have had no evidence of disease at their initial rhTSH stimulation test performed 1 year after the treatment.

      Material and methods

      A retrospective chart review of 278 patients with DTC who had repeated rhTSH stimulation testing after an initial undetectable rhTSH-stimulated serum Tg level.


      The number of rhTSH stimulation tests performed on individual patients during the follow-up period (3–12 years, mean 6·3) varied from two to seven. Biochemical and/or cytological evidence of potential persistent/recurrent disease based on detectable second or third rhTSH-stimulated Tg values and US findings was observed in 11 (4%) patients. Subsequent follow-up data revealed that in five cases, the results of the second stimulation were false positive, in one case – false negative. Combined with the negative neck US, the negative predictive value for disease-free survival was 98% after the first undetectable rhTSH-stimulated Tg and 100% after the second one.


      In patients with DTC, the intensity of follow-up should be adjusted to new risk estimates evolving with time. The first rhTSH-stimulated Tg is an excellent predictor for remission, independent of clinical stage at presentation. Second negative rhTSH-Tg stimulation is additionally reassuring and can guide less aggressive follow-up by the measurement of nonstimulated Tg and neck US every few years.

    • Pubmed ID:
    • Pubmed Central ID:
    • Document Type:
    • Collection(s):
    • Main Document Checksum:
    • File Type:

    You May Also Like

    Checkout today's featured content at